Gamida Cell Analyst Ratings
JMP Securities Downgrades Gamida Cell (GMDA) to a Hold
Piper Sandler Keeps Their Buy Rating on Gamida Cell (GMDA)
Buy Rating Affirmed for Gamida Cell Amid Omisirge's Market Potential
Needham Reiterates Buy on Gamida Cell, Maintains $6 Price Target
Gamida Cell Analyst Ratings
Analysts Offer Insights on Healthcare Companies: BioAtla (BCAB), Gamida Cell (GMDA) and Sagimet Biosciences, Inc. Class A (SGMT)
Gamida Cell Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Arcturus Therapeutics (ARCT), Gamida Cell (GMDA) and Ardelyx (ARDX)
Vernon Bernardino Recommends 'Buy' for Gamida Cell: Promising Growth Trajectory and Expanding Market Access Underpin the Rating
Buy Rating Justified: Gamida Cell's Progress and Strategic Moves Despite Capital Constraints
Gamida Cell's Promising Financial Growth and Potential for Non-Dilutive Capital Leads to Buy Rating
Analysts Offer Insights on Healthcare Companies: Gamida Cell (GMDA) and Ocular Therapeutix (OCUL)
JMP Securities Reiterates Market Outperform on Gamida Cell, Maintains $6 Price Target
Gamida Cell Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Gamida Cell (GMDA) and Paycor HCM (PYCR)
Gamida Cell Analyst Ratings
H.C. Wainwright Sticks to Its Buy Rating for Gamida Cell (GMDA)
Gamida Cell Analyst Ratings
Gamida Cell (GMDA) Gets a Buy From JMP Securities
No Data
No Data